{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.8","value":"244"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received alectinib at a dose of 600 mg via capsule, orally, twice daily, continuously starting on Day 1 Cycle 1 (in 28-day cycles) until PD, death, or withdrawal for any other reasons, whichever occurred first. After PD, participants were allowed to continue treatment with alectinib as per the discretion of the treating physician.","id":"OG000","title":"Alectinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Analysis was performed on PK Evaluable Population. Here, 'Overall Number of Participants Analyzed'=number of participant evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hrs) on Day 21 of Cycle 1","title":"Ctrough of Alectinib Metabolite","type":"SECONDARY","unitOfMeasure":"ng/mL"}